MedImmune, the global biologics research and development arm of pharmaceutical giant AstraZeneca, and the University of Maryland, Baltimore (UMB) have entered into a five-year, $6 million collaboration to drive novel bioscience research in Maryland.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.